Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.3 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
779794
Market Cap
741.10M

Momentum Score

…

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.07
Low
2.34
High
52 Week Price Range
8.08
Low
14.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage company developing targeted oncology therapies aimed at genetically defined tumor subtypes. Major long-term growth drivers include progress in clinical trials, regulatory approvals, and partnerships or licensing for commercial development. Investors may find the company attractive because its precision-medicine focus could produce high-value, milestone-driven upside if programs succeed.

The primary investment risks are clinical and regulatory setbacks, high cash burn and financing needs, and competition from larger oncology developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.30
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-48.23%
Net Debt
-370.92M
ROCE
-35.28%
Diluted EPS TTM
-4.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -134.04M -74.28M -64.70M -0.00M -0.04M
Net income -134.04M -74.28M -64.70M -0.00M -0.04M
Selling general administrative 24.62M 7.76M 8.48M 0.00M 0.07M
Gross profit -0.61M - - - -
Reconciled depreciation 0.61M 0.21M 0.09M - -
Ebit - -80.86M -64.77M - -
Ebitda -145.82M -80.66M -64.68M -0.00M -0.04M
Depreciation and amortization - 0.21M 0.09M - -
Operating income -145.82M -80.86M -64.77M -0.00M -0.04M
Other operating expenses 145.82M 80.86M 64.77M 0.00M 0.04M
Interest income 11.34M 6.38M 0.07M - -
Net interest income 11.34M 6.38M 0.07M - -
Total revenue 0.00M 0.00M 0.00M - -
Total operating expenses 145.82M 80.86M 64.77M 0.00M 0.04M
Cost of revenue 0.61M - - - -
Total other income expense net 11.78M 8.18M 0.07M - 0.00M
Net income from continuing ops -134.04M -74.28M -64.70M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 448.38M 194.42M 0.33M 0.14M 0.14M
Other current assets -0.39M 0.25M 1.96M - -
Total liab 37.28M 5.71M 0.40M 0.17M 0.16M
Total stockholder equity 411.10M 188.72M -0.06M -0.02M -0.02M
Other current liab 33.15M 0.19M 0.33M 0.12M 0.13M
Common stock 0.01M 192.45M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M - -
Retained earnings -356.57M -3.73M -0.09M -0.05M -0.04M
Cash 373.69M 1.70M 0.25M - -
Total current liabilities 35.04M 0.19M 0.40M 0.17M 0.16M
Net debt -370.92M -1.70M 0.07M 0.04M 0.04M
Short term debt 0.52M - 0.07M 0.04M 0.04M
Short long term debt total 2.77M - 0.07M 0.04M 0.04M
Other stockholder equity 767.64M - 0.02M 0.02M 0.02M
Total current assets 425.46M 1.95M 3.94M - -
Short term investments 51.77M 124.78M 0.00M - -
Net receivables 0.39M - - - -
Accounts payable 1.37M 3.07M 0.57M - -
Accumulated other comprehensive income 0.02M - - - -
Non currrent assets other 22.79M 0.03M 0.33M 0.14M 0.14M
Non current assets total 22.92M 192.47M 0.33M 0.14M 0.14M
Capital lease obligations 2.77M 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 73.93M -120.53M -2.82M - -
Total cashflows from investing activities 73.33M -184.00M - - -
Total cash from financing activities 383.40M 186.46M 55.12M - -
Net income -134.04M 7.60M -0.04M -0.00M -0.00M
Change in cash 342.84M 1.70M 0.23M - -
Begin period cash flow 30.98M 0.25M 0.03M - -
End period cash flow 373.82M 1.70M 0.25M 0.03M -
Total cash from operating activities -113.89M -0.76M -52.08M - -
Issuance of capital stock 22.22M 206.24M 55.12M - -
Depreciation 0.61M 0.21M 0.09M - -
Other cashflows from financing activities -12.32M -0.58M - - -
Capital expenditures 0.61M 0.05M 0.41M 0.00M 0.00M
Change in working capital 6.43M -0.10M 0.01M - -
Stock based compensation 5.87M 0.27M 16.46M - -
Other non cash items 7.23M -8.53M 0.03M 0.00M 0.00M
Free cash flow -114.50M -0.76M -52.49M - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
BBOT
BridgeBio Oncology Therapeutics, Inc.		 -
-%		 2.30 - - - 1.80
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

256 East Grand Avenue, South San Francisco, CA, United States, 94080

650 405 4770

https://bbotx.com

92

Name Title Year Born
Mr. Eli M. Wallace Ph.D. CEO & Director 1968
Dr. Pedro J. Beltran M.D., Ph.D. Chief Scientific Officer 1971
Dr. Yong Ben M.B.A., M.D. Chief Medical & Development Officer 1974
Mr. Uneek Mehra M.B.A. Chief Financial Officer 1973
Mr. Howard Y. Chang M.D., Ph.D. Vice President of Operations NA
Mr. Aaron Chan J.D. Vice President of Legal NA
Ms. Angela Peters Senior Vice President of People NA
Mr. Idan Elmelech M.A., M.B.A. Senior VP of Strategy & Business Development NA
Mr. Bin Wang Ph.D. Senior Vice President of Drug Discovery NA
Mr. Daniel Watson Ph.D. Senior Vice President of Chemistry, Manufacturing & Controls NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…